Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07176312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Study acronym: ZANGEA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 8 of 20 sitesv4
  2. Study sites: 1 to 20
    • Start date changed from estimate of Jan 2026 to Jan 16, 2026
    • Collaborators expanded, about 2 words
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2025 to Jan 2026
    • Study sites: 0 to 1
    • Study title shortened, about 4 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.
Trial Details
NCT Number NCT07176312
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Jazz Pharmaceuticals
Conditions
(from sponsor)		 Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1, Metastases
Related terms Neoplasm Metastasis, Stomach Neoplasms
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov